{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T15:10:23Z","timestamp":1792509023802,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T00:00:00Z","timestamp":1707696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Immune checkpoint inhibitors (ICIs) are a revolutionary class of drugs that powerfully contribute to cancer therapy by harnessing the immune system to fight malignancies. However, their successful use as anti-cancer drugs is accompanied by a wide spectrum of immune-related adverse effects (irAEs), including endocrinopathies. Among them, thyroid dysfunction stands out as one of the most common endocrinopathies induced by ICI therapy and surfaces as a prominent concern. Destructive thyroiditis is the pathophysiological basis shared by the most common patterns of thyrotoxicosis followed by hypothyroidism and isolated hypothyroidism. Diagnostic approach is guided by clinical manifestation, laboratory evaluation and imaging modalities. Treatment approaches range from the substitution of levothyroxine to the utilization of beta blockers, depending on the extent of thyroid dysfunction\u2019s severity. While the medical community is dealing with the evolution and complexities of immunotherapy, recognizing and effectively managing ICI-induced thyroid dysfunction emerged as crucial for enhancing patient safety and achieving improved outcomes. The aim of this review is to navigate the significance of ICI-induced thyroid dysfunction unraveling the various patterns, underlying mechanisms, diagnostic approaches, and treatment strategies. It, also, highlights the impact of various factors such as cancer subtype, ICI dosage, age, and genetic susceptibility on the risk of experiencing dysfunction.<\/jats:p>","DOI":"10.1007\/s12020-024-03718-2","type":"journal-article","created":{"date-parts":[[2024,2,12]],"date-time":"2024-02-12T02:02:02Z","timestamp":1707703322000},"page":"67-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Thyroid disorders induced by immune checkpoint inhibitors"],"prefix":"10.1007","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2220-1152","authenticated-orcid":false,"given":"Dimitra","family":"Karaviti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-6549-9002","authenticated-orcid":false,"given":"Eleni-Rafaela","family":"Kani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2938-0889","authenticated-orcid":false,"given":"Eleftheria","family":"Karaviti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4539-8319","authenticated-orcid":false,"given":"Eleni","family":"Gerontiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olympia","family":"Michalopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katerina","family":"Stefanaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paraskevi","family":"Kazakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasiliki","family":"Vasileiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodora","family":"Psaltopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0651-1376","authenticated-orcid":false,"given":"Stavroula A.","family":"Paschou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,12]]},"reference":[{"issue":"6","key":"3718_CR1","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","volume":"187","author":"ES Husebye","year":"2022","unstructured":"E.S. Husebye, F. Castinetti, S. Criseno, G. Curigliano, B. Decallonne, M. Fleseriu, C.E. Higham, I. Lupi, S.A. Paschou, M. Toth, M. van der Kooij, O.M. Dekkers, Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An ESE clinical practice guideline. Eur. J. Endocrinol. 187(6), G1\u2013G21 (2022). https:\/\/doi.org\/10.1530\/EJE-22-0689","journal-title":"Eur. J. Endocrinol."},{"issue":"5","key":"3718_CR2","doi-asserted-by":"publisher","first-page":"e145186, 145186","DOI":"10.1172\/JCI145186","volume":"131","author":"J Moslehi","year":"2021","unstructured":"J. Moslehi, A.H. Lichtman, A.H. Sharpe, L. Galluzzi, R.N. Kitsis, Immune checkpoint inhibitor-associated myocarditis: Manifestations and mechanisms. J. Clin. Investig. 131(5), e145186, 145186 (2021). https:\/\/doi.org\/10.1172\/JCI145186","journal-title":"J. Clin. Investig."},{"issue":"7","key":"3718_CR3","doi-asserted-by":"publisher","first-page":"Article 7","DOI":"10.3390\/jcm9072033","volume":"9","author":"N Okura","year":"2020","unstructured":"N. Okura, M. Asano, J. Uchino, Y. Morimoto, M. Iwasaku, Y. Kaneko, T. Yamada, M. Fukui, K. Takayama, Endocrinopathies associated with immune checkpoint inhibitor cancer treatment: A review. J. Clin. Med. 9(7), Article 7 (2020). https:\/\/doi.org\/10.3390\/jcm9072033","journal-title":"J. Clin. Med."},{"key":"3718_CR4","doi-asserted-by":"crossref","unstructured":"Z. Cardona, J.A. Sosman, S. Chandra, W Huang, Endocrine side effects of immune checkpoint inhibitors. Front Endocrinol 14 (2023). https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1157805","DOI":"10.3389\/fendo.2023.1157805"},{"issue":"4","key":"3718_CR5","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/cen.13297","volume":"86","author":"DL Morganstein","year":"2017","unstructured":"D.L. Morganstein, Z. Lai, L. Spain, S. Diem, D. Levine, C. Mace, M. Gore, J. Larkin, Thyroid abnormalities following the use of cytotoxic T-lymphocyte antigen-4 and programmed death receptor protein-1 inhibitors in the treatment of melanoma. Clin. Endocrinol. 86(4), 614\u2013620 (2017). https:\/\/doi.org\/10.1111\/cen.13297","journal-title":"Clin. Endocrinol."},{"issue":"12","key":"3718_CR6","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1158\/2326-6066.CIR-17-0208","volume":"5","author":"H Lee","year":"2017","unstructured":"H. Lee, F.S. Hodi, A. Giobbie-Hurder, P.A. Ott, E.I. Buchbinder, R. Haq, S. Tolaney, R. Barroso-Sousa, K. Zhang, H. Donahue, M. Davis, M.E. Gargano, K.M. Kelley, R.S. Carroll, U.B. Kaiser, L. Min, Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy. Cancer Immunol. Res. 5(12), 1133\u20131140 (2017). https:\/\/doi.org\/10.1158\/2326-6066.CIR-17-0208","journal-title":"Cancer Immunol. Res."},{"issue":"5","key":"3718_CR7","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s40618-017-0772-1","volume":"41","author":"F Guaraldi","year":"2018","unstructured":"F. Guaraldi, R. La Selva, M.T. Sam\u00e0, V. D\u2019Angelo, D. Gori, P. Fava, M.T. Fierro, P. Savoia, E. Arvat, Characterization and implications of thyroid dysfunction induced by immune checkpoint inhibitors in real-life clinical practice: A long-term prospective study from a referral institution. J. Endocrinol. Investig. 41(5), 549\u2013556 (2018). https:\/\/doi.org\/10.1007\/s40618-017-0772-1","journal-title":"J. Endocrinol. Investig."},{"issue":"10","key":"3718_CR8","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1089\/thy.2020.0075","volume":"30","author":"A Kotwal","year":"2020","unstructured":"A. Kotwal, M.P. Gustafson, S. Bornschlegl, L. Kottschade, D.A. Delivanis, A.B. Dietz, M. Gandhi, M. Ryder, Immune checkpoint inhibitor-induced thyroiditis is associated with increased intrathyroidal T lymphocyte subpopulations. Thyroid 30(10), 1440\u20131450 (2020). https:\/\/doi.org\/10.1089\/thy.2020.0075","journal-title":"Thyroid"},{"issue":"11","key":"3718_CR9","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1210\/jc.2016-2300","volume":"101","author":"J de Filette","year":"2016","unstructured":"J. de Filette, Y. Jansen, M. Schreuer, H. Everaert, B. Velkeniers, B. Neyns, B. Bravenboer, Incidence of thyroid-related adverse events in melanoma patients treated with pembrolizumab. J. Clin. Endocrinol. Metab. 101(11), 4431\u20134439 (2016). https:\/\/doi.org\/10.1210\/jc.2016-2300","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3718_CR10","doi-asserted-by":"publisher","first-page":"e2087525","DOI":"10.1155\/2016\/2087525","volume":"2016","author":"U Azmat","year":"2016","unstructured":"U. Azmat, D. Liebner, A. Joehlin-Price, A. Agrawal, F. Nabhan, Treatment of ipilimumab induced graves\u2019 disease in a patient with metastatic melanoma. Case Rep. Endocrinol. 2016, e2087525 (2016). https:\/\/doi.org\/10.1155\/2016\/2087525","journal-title":"Case Rep. Endocrinol."},{"issue":"3","key":"3718_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000464285","volume":"6","author":"EH Gan","year":"2017","unstructured":"E.H. Gan, A.L. Mitchell, R. Plummer, S. Pearce, P. Perros, Tremelimumab-induced graves hyperthyroidism. Eur. Thyroid J. 6(3), 167\u2013170 (2017). https:\/\/doi.org\/10.1159\/000464285","journal-title":"Eur. Thyroid J."},{"issue":"21","key":"3718_CR12","doi-asserted-by":"publisher","first-page":"Article 21","DOI":"10.3390\/cancers13215277","volume":"13","author":"MV Deligiorgi","year":"2021","unstructured":"M.V. Deligiorgi, S. Sagredou, L. Vakkas, D.T. Trafalis, The continuum of thyroid disorders related to immune checkpoint inhibitors: STill Many Pending Queries. Cancers 13(21), Article 21 (2021). https:\/\/doi.org\/10.3390\/cancers13215277","journal-title":"Cancers"},{"issue":"1","key":"3718_CR13","doi-asserted-by":"publisher","first-page":"100011","DOI":"10.1016\/j.esmoop.2020.100011","volume":"6","author":"SA Paschou","year":"2021","unstructured":"S.A. Paschou, K. Stefanaki, T. Psaltopoulou, M. Liontos, K. Koutsoukos, F. Zagouri, I. Lambrinoudaki, M.-A. Dimopoulos, How we treat endocrine complications of immune checkpoint inhibitors. ESMO Open 6(1), 100011 (2021). https:\/\/doi.org\/10.1016\/j.esmoop.2020.100011","journal-title":"ESMO Open"},{"issue":"3","key":"3718_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.6004\/jnccn.2019.0013","volume":"17","author":"JA Thompson","year":"2019","unstructured":"J.A. Thompson, B.J. Schneider, J. Brahmer, S. Andrews, P. Armand, S. Bhatia, L.E. Budde, L. Costa, M. Davies, D. Dunnington, M.S. Ernstoff, M. Frigault, B. Hoffner, C.J. Hoimes, M. Lacouture, F. Locke, M. Lunning, N.A. Mohindra, J. Naidoo, J.L. Scavone, Management of immunotherapy-related toxicities, Version 1.2019, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Cancer Netw. 17(3), 255\u2013289 (2019). https:\/\/doi.org\/10.6004\/jnccn.2019.0013","journal-title":"J. Natl. Compr. Cancer Netw."},{"issue":"7","key":"3718_CR15","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/j.eprac.2022.04.010","volume":"28","author":"KCJ Yuen","year":"2022","unstructured":"K.C.J. Yuen, S.L. Samson, I. Bancos, A.R. Gosmanov, S. Jasim, L.A. Fecher, J.S. Weber, American association of clinical endocrinology disease state clinical review: Evaluation and management of immune checkpoint inhibitor-mediated endocrinopathies: A practical case-based clinical approach. Endocr. Pract. 28(7), 719\u2013731 (2022). https:\/\/doi.org\/10.1016\/j.eprac.2022.04.010","journal-title":"Endocr. Pract."},{"issue":"10","key":"3718_CR16","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1089\/thy.2017.0062","volume":"27","author":"K Torimoto","year":"2017","unstructured":"K. Torimoto, Y. Okada, S. Nakayamada, S. Kubo, Y. Tanaka, Anti-PD-1 antibody therapy induces hashimoto\u2019s disease with an increase in peripheral blood follicular helper T cells. Thyroid 27(10), 1335\u20131336 (2017). https:\/\/doi.org\/10.1089\/thy.2017.0062","journal-title":"Thyroid"},{"issue":"5","key":"3718_CR17","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.21873\/invivo.11166","volume":"31","author":"T Maekura","year":"2017","unstructured":"T. Maekura, M. Naito, M. Tahara, N. Ikegami, Y. Kimura, S. Sonobe, T. Kobayashi, T. Tsuji, S. Minomo, A. Tamiya, S. Atagi, Predictive factors of nivolumab-induced hypothyroidism in patients with non-small cell lung cancer. Vivo 31(5), 1035\u20131039 (2017). https:\/\/doi.org\/10.21873\/invivo.11166","journal-title":"Vivo"},{"issue":"3","key":"3718_CR18","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1093\/annonc\/mdw640","volume":"28","author":"JC Osorio","year":"2017","unstructured":"J.C. Osorio, A. Ni, J.E. Chaft, R. Pollina, M.K. Kasler, D. Stephens, C. Rodriguez, L. Cambridge, H. Rizvi, J.D. Wolchok, T. Merghoub, C.M. Rudin, S. Fish, M.D. Hellmann, Antibody-mediated thyroid dysfunction during T-cell checkpoint blockade in patients with non-small-cell lung cancer. Ann. Oncol. 28(3), 583\u2013589 (2017). https:\/\/doi.org\/10.1093\/annonc\/mdw640","journal-title":"Ann. Oncol."},{"issue":"10","key":"3718_CR19","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1089\/thy.2020.0032","volume":"30","author":"CA Muir","year":"2020","unstructured":"C.A. Muir, A.M. Menzies, R. Clifton-Bligh, V.H.M. Tsang, Thyroid toxicity following immune checkpoint inhibitor treatment in advanced cancer. Thyroid 30(10), 1458\u20131469 (2020). https:\/\/doi.org\/10.1089\/thy.2020.0032","journal-title":"Thyroid"},{"issue":"10","key":"3718_CR20","doi-asserted-by":"publisher","first-page":"e1056","DOI":"10.1210\/clinem\/dgad231","volume":"108","author":"X Zhou","year":"2023","unstructured":"X. Zhou, S. Iwama, T. Kobayashi, M. Ando, H. Arima, Risk of thyroid dysfunction in PD-1 blockade is stratified by the pattern of TgAb and TPOAb positivity at baseline. J. Clin. Endocrinol. Metab. 108(10), e1056\u2013e1062 (2023). https:\/\/doi.org\/10.1210\/clinem\/dgad231","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"8","key":"3718_CR21","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1210\/jc.2017-00448","volume":"102","author":"DA Delivanis","year":"2017","unstructured":"D.A. Delivanis, M.P. Gustafson, S. Bornschlegl, M.M. Merten, L. Kottschade, S. Withers, A.B. Dietz, M. Ryder, Pembrolizumab-induced thyroiditis: Comprehensive clinical review and insights into underlying involved mechanisms. J. Clin. Endocrinol. Metab. 102(8), 2770\u20132780 (2017). https:\/\/doi.org\/10.1210\/jc.2017-00448","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"5","key":"3718_CR22","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1111\/cas.14363","volume":"111","author":"C Kurimoto","year":"2020","unstructured":"C. Kurimoto, H. Inaba, H. Ariyasu, H. Iwakura, Y. Ueda, S. Uraki, K. Takeshima, Y. Furukawa, S. Morita, Y. Yamamoto, S. Yamashita, M. Katsuda, A. Hayata, H. Akamatsu, M. Jinnin, I. Hara, H. Yamaue, T. Akamizu, Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors. Cancer Sci. 111(5), 1468\u20131477 (2020). https:\/\/doi.org\/10.1111\/cas.14363","journal-title":"Cancer Sci."},{"key":"3718_CR23","doi-asserted-by":"crossref","unstructured":"L. Zhan, H. Feng, H. Liu, L. Guo, C. Chen, X. Yao, S Sun, Immune checkpoint inhibitors-related thyroid dysfunction: Epidemiology, clinical presentation, possible pathogenesis, and management. Front. Endocrinol. 12 (2021). https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2021.649863","DOI":"10.3389\/fendo.2021.649863"},{"issue":"4","key":"3718_CR24","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1159\/000501824","volume":"8","author":"A Brancatella","year":"2019","unstructured":"A. Brancatella, N. Viola, S. Brogioni, L. Montanelli, C. Sardella, P. Vitti, C. Marcocci, I. Lupi, F. Latrofa, Graves\u2019 disease induced by immune checkpoint inhibitors: A case report and review of the literature. Eur. Thyroid J. 8(4), 192\u2013195 (2019). https:\/\/doi.org\/10.1159\/000501824","journal-title":"Eur. Thyroid J."},{"issue":"4","key":"3718_CR25","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1530\/EC-19-0473","volume":"9","author":"A Olsson-Brown","year":"2020","unstructured":"A. Olsson-Brown, R. Lord, J. Sacco, J. Wagg, M. Coles, M. Pirmohamed, Two distinct clinical patterns of checkpoint inhibitor-induced thyroid dysfunction. Endocr. Connect. 9(4), 318\u2013325 (2020). https:\/\/doi.org\/10.1530\/EC-19-0473","journal-title":"Endocr. Connect."},{"issue":"2","key":"3718_CR26","doi-asserted-by":"publisher","first-page":"e126","DOI":"10.1093\/oncolo\/oyab043","volume":"27","author":"D Lu","year":"2022","unstructured":"D. Lu, J. Yao, G. Yuan, Y. Gao, J. Zhang, X. Guo, Immune checkpoint inhibitor-related new-onset thyroid dysfunction: A retrospective analysis using the US FDA adverse event reporting system. Oncologist 27(2), e126\u2013e132 (2022). https:\/\/doi.org\/10.1093\/oncolo\/oyab043","journal-title":"Oncologist"},{"issue":"10","key":"3718_CR27","doi-asserted-by":"publisher","first-page":"R207","DOI":"10.1530\/EC-20-0342","volume":"9","author":"M Stelmachowska-Bana\u015b","year":"2020","unstructured":"M. Stelmachowska-Bana\u015b, I. Czajka-Oraniec, Management of endocrine immune-related adverse events of immune checkpoint inhibitors: An updated review. Endocr. Connect. 9(10), R207\u2013R228 (2020). https:\/\/doi.org\/10.1530\/EC-20-0342","journal-title":"Endocr. Connect."},{"issue":"4","key":"3718_CR28","doi-asserted-by":"publisher","first-page":"559","DOI":"10.4103\/ijmr.IJMR_313_19","volume":"154","author":"I Goyal","year":"2021","unstructured":"I. Goyal, M.R. Pandey, R. Sharma, A. Chaudhuri, P. Dandona, The side effects of immune checkpoint inhibitor therapy on the endocrine system. Indian J. Med. Res. 154(4), 559 (2021). https:\/\/doi.org\/10.4103\/ijmr.IJMR_313_19","journal-title":"Indian J. Med. Res."},{"issue":"4","key":"3718_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1634\/theoncologist.2018-0470","volume":"25","author":"J Del Rivero","year":"2020","unstructured":"J. Del Rivero, L.M. Cordes, J. Klubo\u2010Gwiezdzinska, R.A. Madan, L.K. Nieman, J.L. Gulley, Endocrine\u2010related adverse events related to immune checkpoint inhibitors: Proposed algorithms for management. Oncologist 25(4), 290\u2013300 (2020). https:\/\/doi.org\/10.1634\/theoncologist.2018-0470","journal-title":"Oncologist"},{"issue":"1","key":"3718_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1210\/er.2018-00006","volume":"40","author":"L-S Chang","year":"2019","unstructured":"L.-S. Chang, R. Barroso-Sousa, S.M. Tolaney, F.S. Hodi, U.B. Kaiser, L. Min, Endocrine toxicity of cancer immunotherapy targeting immune checkpoints. Endocr. Rev. 40(1), 17\u201365 (2019). https:\/\/doi.org\/10.1210\/er.2018-00006","journal-title":"Endocr. Rev."},{"key":"3718_CR31","doi-asserted-by":"publisher","unstructured":"J. Villadolid, A. Amin, Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. Transl. Lung Cancer Res. 4(5) (2015). https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2015.06.06","DOI":"10.3978\/j.issn.2218-6751.2015.06.06"},{"issue":"4","key":"3718_CR32","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1111\/1759-7714.13347","volume":"11","author":"L Duan","year":"2020","unstructured":"L. Duan, L. Wang, H. Wang, X. Si, L. Zhang, X. Liu, Y. Li, X. Guo, J. Zhou, H. Zhu, L. Zhang, Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction. Thorac. Cancer 11(4), 1099\u20131104 (2020). https:\/\/doi.org\/10.1111\/1759-7714.13347","journal-title":"Thorac. Cancer"},{"key":"3718_CR33","doi-asserted-by":"crossref","unstructured":"S. A. Paschou, M. Liontos, E. Eleftherakis-Papaiakovou, K. Stefanaki, C. Markellos, K. Koutsoukos, F. Zagouri, T. Psaltopoulou, M.-A Dimopoulos, Oncological patients with endocrine complications after immunotherapy with checkpoint inhibitors present longer progression-free and overall survival. Front. Oncol. 12 (2022). https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.847917","DOI":"10.3389\/fonc.2022.847917"},{"issue":"3","key":"3718_CR34","doi-asserted-by":"publisher","first-page":"R116","DOI":"10.1530\/EC-20-0489","volume":"10","author":"B Anderson","year":"2021","unstructured":"B. Anderson, D.L. Morganstein, Endocrine toxicity of cancer immunotherapy: Clinical challenges. Endocr. Connect. 10(3), R116\u2013R124 (2021). https:\/\/doi.org\/10.1530\/EC-20-0489","journal-title":"Endocr. Connect."},{"issue":"7","key":"3718_CR35","doi-asserted-by":"publisher","first-page":"Article 7","DOI":"10.1038\/s41574-021-00484-3","volume":"17","author":"JJ Wright","year":"2021","unstructured":"J.J. Wright, A.C. Powers, D.B. Johnson, Endocrine toxicities of immune checkpoint inhibitors. Nat. Rev. Endocrinol. 17(7), Article 7 (2021). https:\/\/doi.org\/10.1038\/s41574-021-00484-3","journal-title":"Nat. Rev. Endocrinol."},{"issue":"15","key":"3718_CR36","doi-asserted-by":"publisher","first-page":"6585","DOI":"10.1002\/cam4.2533","volume":"8","author":"E Kassi","year":"2019","unstructured":"E. Kassi, A. Angelousi, N. Asonitis, P. Diamantopoulos, A. Anastasopoulou, G. Papaxoinis, M. Kokkinos, I. Giovanopoulos, G. Kyriakakis, F. Petychaki, A. Savelli, O. Benopoulou, H. Gogas, Endocrine-related adverse events associated with immune-checkpoint inhibitors in patients with melanoma. Cancer Med. 8(15), 6585\u20136594 (2019). https:\/\/doi.org\/10.1002\/cam4.2533","journal-title":"Cancer Med."},{"key":"3718_CR37","doi-asserted-by":"publisher","first-page":"1010279","DOI":"10.3389\/fendo.2022.1010279","volume":"13","author":"A Chera","year":"2022","unstructured":"A. Chera, A.L. Stancu, O. Bucur, Thyroid-related adverse events induced by immune checkpoint inhibitors. Front. Endocrinol. 13, 1010279 (2022). https:\/\/doi.org\/10.3389\/fendo.2022.1010279","journal-title":"Front. Endocrinol."},{"issue":"2","key":"3718_CR38","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1002\/cpt.1597","volume":"107","author":"S Yang","year":"2020","unstructured":"S. Yang, K.-H. Yu, N. Palmer, K. Fox, S.C. Kou, I.S. Kohane, Autoimmune effects of lung cancer immunotherapy revealed by data-driven analysis on a nationwide cohort. Clin. Pharmacol. Ther. 107(2), 388\u2013396 (2020). https:\/\/doi.org\/10.1002\/cpt.1597","journal-title":"Clin. Pharmacol. Ther."},{"issue":"4","key":"3718_CR39","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1056\/NEJMoa1805131","volume":"379","author":"MR Migden","year":"2018","unstructured":"M.R. Migden, D. Rischin, C.D. Schmults, A. Guminski, A. Hauschild, K.D. Lewis, C.H. Chung, L. Hernandez-Aya, A.M. Lim, A.L.S. Chang, G. Rabinowits, A.A. Thai, L.A. Dunn, B.G.M. Hughes, N.I. Khushalani, B. Modi, D. Schadendorf, B. Gao, F. Seebach, M.G. Fury, PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl. J. Med. 379(4), 341\u2013351 (2018). https:\/\/doi.org\/10.1056\/NEJMoa1805131","journal-title":"N. Engl. J. Med."},{"key":"3718_CR40","doi-asserted-by":"publisher","unstructured":"L. Trudu, G. Guaitoli, F. Bertolini, M. Maur, C. Santini, V. R. Papapietro, S. Talerico, S. Natalizio, C. Isca, M. Dominici, F. Barbieri, Thyroid function impairment after chemo-immunotherapy for advanced NSCLC: A single institutional retrospective report. Immunotherapy (2022). https:\/\/doi.org\/10.2217\/imt-2021-0165","DOI":"10.2217\/imt-2021-0165"},{"issue":"16_suppl","key":"3718_CR41","doi-asserted-by":"publisher","first-page":"2654","DOI":"10.1200\/JCO.2022.40.16_suppl.2654","volume":"40","author":"LL Prather","year":"2022","unstructured":"L.L. Prather, A. Ali, H. Wang, W. Du, N. Chen, A. Sheth, V. Sandulache, A.L. Sabichi, J.O. Kemnade, D.Y. Wang, Immune-related adverse events and immunotherapy efficacy in patients with cancer: A retrospective study. J. Clin. Oncol. 40(16_suppl), 2654\u20132654 (2022). https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2654","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"3718_CR42","doi-asserted-by":"publisher","first-page":"e220065","DOI":"10.1530\/EC-22-0065","volume":"11","author":"X Zheng","year":"2022","unstructured":"X. Zheng, H. Xiao, J. Long, Q. Wei, L. Liu, L. Zan, W. Ren, Dynamic follow-up of the effects of programmed death 1 inhibitor treatment on thyroid function and sonographic features in patients with hepatocellular carcinoma. Endocr. Connect. 11(5), e220065 (2022). https:\/\/doi.org\/10.1530\/EC-22-0065","journal-title":"Endocr. Connect."},{"issue":"1","key":"3718_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-022-01004-8","volume":"22","author":"H-S Baek","year":"2022","unstructured":"H.-S. Baek, C. Jeong, K. Shin, J. Lee, H. Suh, D.-J. Lim, M.I. Kang, J. Ha, Association between the type of thyroid dysfunction induced by immune checkpoint inhibitors and prognosis in cancer patients. BMC Endocr. Disord. 22(1), 89 (2022). https:\/\/doi.org\/10.1186\/s12902-022-01004-8","journal-title":"BMC Endocr. Disord."},{"issue":"2","key":"3718_CR44","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1089\/thy.2019.0250","volume":"30","author":"A Kotwal","year":"2020","unstructured":"A. Kotwal, L. Kottschade, M. Ryder, PD-L1 inhibitor-induced thyroiditis is associated with better overall survival in cancer patients. Thyroid 30(2), 177\u2013184 (2020). https:\/\/doi.org\/10.1089\/thy.2019.0250","journal-title":"Thyroid"},{"issue":"2","key":"3718_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s00262-020-02664-y","volume":"70","author":"J Lima Ferreira","year":"2021","unstructured":"J. Lima Ferreira, C. Costa, B. Marques, S. Castro, M. Victor, J. Oliveira, A.P. Santos, I.L. Sampaio, H. Duarte, A.P. Marques, I. Torres, Improved survival in patients with thyroid function test abnormalities secondary to immune-checkpoint inhibitors. Cancer Immunol. Immunotherapy 70(2), 299\u2013309 (2021). https:\/\/doi.org\/10.1007\/s00262-020-02664-y","journal-title":"Cancer Immunol. Immunotherapy"},{"issue":"5","key":"3718_CR46","doi-asserted-by":"publisher","first-page":"496","DOI":"10.3892\/ol.2023.14083","volume":"26","author":"X Li","year":"2023","unstructured":"X. Li, X. Wang, S. Wang, Y. Liu, R. Wang, Y. Liu, L. Huang, Y. Feng, X. Xie, L. Shi, Thyroid dysfunction induced by immune checkpoint inhibitors and tumor progression during neoadjuvant therapy of non\u2011small cell lung cancer: A case report and literature review. Oncol. Lett. 26(5), 496 (2023). https:\/\/doi.org\/10.3892\/ol.2023.14083","journal-title":"Oncol. Lett."},{"issue":"3","key":"3718_CR47","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1007\/s00259-020-05052-x","volume":"48","author":"P Petranovi\u0107 Ov\u010dari\u010dek","year":"2021","unstructured":"P. Petranovi\u0107 Ov\u010dari\u010dek, F.A. Verburg, M. Hoffmann, I. Iakovou, J. Mihailovic, A. Vrachimis, M. Luster, L. Giovanella, Correction to: Higher thyroid hormone levels and cancer. Eur. J. Nucl. Med. Mol. Imaging 48(3), 951\u2013953 (2021). https:\/\/doi.org\/10.1007\/s00259-020-05052-x","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"issue":"9","key":"3718_CR48","doi-asserted-by":"publisher","first-page":"2183","DOI":"10.1007\/s00262-022-03218-0","volume":"71","author":"MS von Itzstein","year":"2022","unstructured":"M.S. von Itzstein, A.S. Gonugunta, Y. Wang, T. Sheffield, R. Lu, S. Ali, F.J. Fattah, D. Xie, J. Cai, Y. Xie, D.E. Gerber, Correction to: Divergent prognostic effects of pre-existing and treatment-emergent thyroid dysfunction in patients treated with immune checkpoint inhibitors. Cancer Immunol., Immunotherapy: CII 71(9), 2183\u20132184 (2022). https:\/\/doi.org\/10.1007\/s00262-022-03218-0","journal-title":"Cancer Immunol., Immunotherapy: CII"},{"issue":"2","key":"3718_CR49","doi-asserted-by":"publisher","first-page":"286","DOI":"10.4183\/aeb.2021.286","volume":"17","author":"S Coniac","year":"2021","unstructured":"S. Coniac, M. Stoian, Updates in endocrine immune-related adverse events in oncology immunotherapy. Acta Endocrinologica (Buchar., Rom.: 2005) 17(2), 286\u2013289 (2021). https:\/\/doi.org\/10.4183\/aeb.2021.286","journal-title":"Acta Endocrinologica (Buchar., Rom.: 2005)"},{"issue":"4","key":"3718_CR50","doi-asserted-by":"publisher","first-page":"Article 4","DOI":"10.1038\/nrendo.2016.205","volume":"13","author":"DJ Byun","year":"2017","unstructured":"D.J. Byun, J.D. Wolchok, L.M. Rosenberg, M. Girotra, Cancer immunotherapy\u2014Immune checkpoint blockade and associated endocrinopathies. Nat. Rev. Endocrinol. 13(4), Article 4 (2017). https:\/\/doi.org\/10.1038\/nrendo.2016.205","journal-title":"Nat. Rev. Endocrinol."},{"issue":"21","key":"3718_CR51","doi-asserted-by":"publisher","first-page":"1572","DOI":"10.1093\/jnci\/djr373","volume":"103","author":"O-PR Hamnvik","year":"2011","unstructured":"O.-P.R. Hamnvik, P.R. Larsen, E. Marqusee, Thyroid dysfunction from antineoplastic agents. J. Natl. Cancer Inst. 103(21), 1572\u20131587 (2011). https:\/\/doi.org\/10.1093\/jnci\/djr373","journal-title":"J. Natl. Cancer Inst."},{"issue":"3","key":"3718_CR52","doi-asserted-by":"publisher","first-page":"pky021","DOI":"10.1093\/jncics\/pky021","volume":"2","author":"M Girotra","year":"2018","unstructured":"M. Girotra, A. Hansen, A. Farooki, D.J. Byun, L. Min, B.C. Creelan, M.K. Callahan, M.B. Atkins, E. Sharon, S.J. Antonia, P. West, A.E. Gravell; Investigational Drug Steering Committee (IDSC) Immunotherapy Task Force collaboration, The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management. JNCI Cancer Spectr. 2(3), pky021 (2018). https:\/\/doi.org\/10.1093\/jncics\/pky021","journal-title":"JNCI Cancer Spectr."},{"issue":"17","key":"3718_CR53","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","volume":"36","author":"JR Brahmer","year":"2018","unstructured":"J.R. Brahmer, C. Lacchetti, B.J. Schneider, M.B. Atkins, K.J. Brassil, J.M. Caterino, I. Chau, M.S. Ernstoff, J.M. Gardner, P. Ginex, S. Hallmeyer, J. Holter Chakrabarty, N.B. Leighl, J.S. Mammen, D.F. McDermott, A. Naing, L.J. Nastoupil, T. Phillips, L.D. Porter; National Comprehensive Cancer Network, Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline. J. Clin. Oncol 36(17), 1714\u20131768 (2018). https:\/\/doi.org\/10.1200\/JCO.2017.77.6385","journal-title":"J. Clin. Oncol"},{"issue":"1","key":"3718_CR54","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z","volume":"5","author":"I Puzanov","year":"2017","unstructured":"I. Puzanov, A. Diab, K. Abdallah, C.O. Bingham, C. Brogdon, R. Dadu, L. Hamad, S. Kim, M.E. Lacouture, N.R. LeBoeuf, D. Lenihan, C. Onofrei, V. Shannon, R. Sharma, A.W. Silk, D. Skondra, M.E. Suarez-Almazor, Y. Wang, K. Wiley, P. Zheng, Managing toxicities associated with immune checkpoint inhibitors: Consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group. J. Immunother. Cancer 5(1), 95 (2017). https:\/\/doi.org\/10.1186\/s40425-017-0300-z","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"3718_CR55","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1507\/endocrj.EJ19-0163","volume":"66","author":"H Arima","year":"2019","unstructured":"H. Arima, S. Iwama, H. Inaba, H. Ariyasu, N. Makita, M. Otsuki, K. Kageyama, A. Imagawa, T. Akamizu, Management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors: Clinical guidelines of the Japan Endocrine Society. Endocr. J. 66(7), 581\u2013586 (2019). https:\/\/doi.org\/10.1507\/endocrj.EJ19-0163","journal-title":"Endocr. J."},{"issue":"2","key":"3718_CR56","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/ERC-18-0320","volume":"26","author":"F Castinetti","year":"2019","unstructured":"F. Castinetti, F. Albarel, F. Archambeaud, J. Bertherat, B. Bouillet, P. Buffier, C. Briet, B. Cariou, P. Caron, O. Chabre, P. Chanson, C. Cortet, C.D. Cao, D. Drui, M. Haissaguerre, S. Hescot, F. Illouz, E. Kuhn, N. Lahlou, F. Borson-Chazot, French Endocrine Society Guidance on endocrine side effects of immunotherapy. Endocr.-Relat. Cancer 26(2), G1\u2013G18 (2019). https:\/\/doi.org\/10.1530\/ERC-18-0320","journal-title":"Endocr.-Relat. Cancer"},{"issue":"7","key":"3718_CR57","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EC-18-0068","volume":"7","author":"CE Higham","year":"2018","unstructured":"C.E. Higham, A. Olsson-Brown, P. Carroll, T. Cooksley, J. Larkin, P. Lorigan, D. Morganstein, P.J. Trainer, Society for endocrinology endocrine emergency guidance: Acute management of the endocrine complications of checkpoint inhibitor therapy. Endocr. Connect. 7(7), G1\u2013G7 (2018). https:\/\/doi.org\/10.1530\/EC-18-0068","journal-title":"Endocr. Connect."},{"key":"3718_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2147\/EB.S277760","volume":"12","author":"CW Yu","year":"2020","unstructured":"C.W. Yu, M. Yau, N. Mezey, I. Joarder, J.A. Micieli, Neuro-ophthalmic complications of immune checkpoint inhibitors: A systematic review. Eye Brain 12, 139\u2013167 (2020). https:\/\/doi.org\/10.2147\/EB.S277760","journal-title":"Eye Brain"}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03718-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03718-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,13]],"date-time":"2024-07-13T05:30:26Z","timestamp":1720848626000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03718-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,12]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["3718"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03718-2","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,12]]},"assertion":[{"value":"13 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}